PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30964194-10	2019	The cytoprotective effects of SDX resulted from a reduction in a) ROS production, b) neo-synthesis and release of pro-inflammatory cytokines (TNFalpha, IL1, IL6, IL8), c) DNA damage induced by MGO or IR.	glucuronyl glucosamine glycan sulfate	30-33	interleukin 6	Homo sapiens	157-160	
19218094-7	2009	Sulodexide caused the inhibition of the intracellular generation of free radicals in a dose-dependent manner (maximally by 32%, P < 0.01), as well as the inhibition of MCP-1 (maximally by 60%, P < 0.001) and IL-6 (maximally by 69%, P < 0.01).	glucuronyl glucosamine glycan sulfate	0-10	interleukin 6	Homo sapiens	214-218	
34075143-12	2021	Additionally, Sulodexide decreases the secretion of IL6 and VEGF-A from senescent HREC and increases their TEER.	glucuronyl glucosamine glycan sulfate	14-24	interleukin 6	Homo sapiens	52-55	
30959503-11	2019	SUL reduced the uremic serum-induced secretion of all solutes: IL6 -24%, p < 0.05; ICAM-1 -43%, p < 0.01; VEGF -38%, p < 0.01; vWF -23%, p < 0.01; t-PA -49%, p < 0.01, and MMP9 -25%, p < 0.05.	glucuronyl glucosamine glycan sulfate	0-3	interleukin 6	Homo sapiens	63-66	
26044841-12	2015	Synthesis of IL-6 was lower in HVEC exposed in vitro to serum collected at the end of SUL treatment: 1.02+-0.31 ng/mug cell protein vs. 1.32+-0.41 ng/mug cell protein before SUL treatment.	glucuronyl glucosamine glycan sulfate	86-89	interleukin 6	Homo sapiens	13-17	
26868135-9	2016	In the supernatants obtained after cell incubation with serum from sulodexide treated patients, the increase in concentrations of IL-6, MCP-1 and ICAM-1 was significantly less than the control.	glucuronyl glucosamine glycan sulfate	67-77	interleukin 6	Homo sapiens	130-134	
27941341-7	2016	Sulodexide (0.5 LRU/mL) reduced atherosclerotic serum-induced increased expression of genes for IL-6 (-32%), VCAM-1 (-20%) and VWF (-42%), and lowered secretion of these molecules: IL-6 (-27%), VCAM-1(-27%), VWF (-25%).	glucuronyl glucosamine glycan sulfate	0-10	interleukin 6	Homo sapiens	96-100	
27941341-7	2016	Sulodexide (0.5 LRU/mL) reduced atherosclerotic serum-induced increased expression of genes for IL-6 (-32%), VCAM-1 (-20%) and VWF (-42%), and lowered secretion of these molecules: IL-6 (-27%), VCAM-1(-27%), VWF (-25%).	glucuronyl glucosamine glycan sulfate	0-10	interleukin 6	Homo sapiens	181-185	
27941341-8	2016	Sulodexide also reduced, in a dose- dependent manner, secretion of IL6 from unstimulated and stimulated with IL-1 endothelial cells.	glucuronyl glucosamine glycan sulfate	0-10	interleukin 6	Homo sapiens	67-70